Description
Added on the 12/09/2020 12:16:30 - Copyright : AFP EN
A new study reveals a COVID-19 vaccine under development in England safely promotes an immune response against the virus. According to UPI, the vaccine is in Phase 2 of clinical trials with Astra Zeneca, and is particularly effective in elderly recipients who are over age 70. Researchers say the finding of the 'robust' responses in older people in their study is both significant and encouraging. The populations at greatest risk of serious COVID-19 disease include people with existing health conditions and older adults. The so-called "Oxford vaccine," formally known as ChAdOx1 nCoV-19, is one of more than 120 being evaluated in response to the COVID-19 pandemic. To date, 48 of these vaccines have gotten into clinical trials to assess their safety and efficacy.
Head of Vaccine Strategy at the European Medicines Agency (EMA) Marco Cavaleri says it is "safe and effective" to issue booster doses of Covid-19 vaccines as soon as three months after the initial course, down from previous guidance of six months. SOUNDBITE
Executive Director of the European Medicines Agency (EMA) Emer Cook says the AstraZeneca vaccine is "safe and effective" and not associated with a higher blood clot risk, after more than a dozen countries paused rollouts over health fears. IMAGES
The President of the European Commission Ursula von der Leyen unveils a plan to set up a travel certificate to help restore freedom of movement within the bloc for citizens inoculated against the coronavirus. SOUNDBITE
WHO director-general Tedros Adhanom Ghebreyesus stresses that the organisation will never back a vaccine that has not proven safe and effective, amid concerns over efforts to rush the development of a jab for Covid-19. SOUNDBITE
|
Support : Technical 
- Content 
- Editors 
